The purpose of the study is to evaluate the effectiveness and safety of the medication for treating the condition. This double‑blinded study lasts for 52 weeks, beginning with a 12‑week initial treatment phase followed by a longer continuation phase. Throughout the trial, participants will apply the assigned cream regularly, attend scheduled visits for health checks, and complete questionnaires about symptoms and quality of life.

The purpose of the study is to assess how effective LY3454738 is in treating adults with moderate-to-severe atopic dermatitis. The study will last for 52 weeks, during which participants will receive regular injections and be monitored for any changes in their condition. The study aims to see if LY3454738 can help reduce the symptoms of atopic dermatitis, such as the extent and severity of the eczema.

Participants will be randomly assigned to receive either the active treatment or the placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a double-blind study. The study will help determine if LY3454738 is a safe and effective option for people with moderate-to-severe atopic dermatitis who have not had significant improvement with topical treatments.